Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ALEXANDER LAZAR and KEILA ENITT TORRES.
ALEXANDER LAZAR
Connection Strength
3.616
KEILA ENITT TORRES
  1. Clinical Variables Influencing Outcomes in Patients with Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single-Institution Study of 95 Surgical Patients. Ann Surg Oncol. 2024 Nov; 31(12):7950-7956.
    View in: PubMed
    Score: 0.246
  2. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor. Lab Invest. 2022 06; 102(6):658-666.
    View in: PubMed
    Score: 0.208
  3. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 2021 09; 142(3):565-590.
    View in: PubMed
    Score: 0.199
  4. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021 03 01; 4(3):e210945.
    View in: PubMed
    Score: 0.194
  5. AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors. J Cancer Sci Clin Ther. 2020; 4(4):511-525.
    View in: PubMed
    Score: 0.189
  6. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. 2017 10 03; 18(10):816-826.
    View in: PubMed
    Score: 0.153
  7. Sarcoma Brain Metastases: 28?Years of Experience at a Single Institution. Ann Surg Oncol. 2016 12; 23(Suppl 5):962-967.
    View in: PubMed
    Score: 0.142
  8. Myxofibrosarcoma. Surg Oncol Clin N Am. 2016 10; 25(4):775-88.
    View in: PubMed
    Score: 0.141
  9. Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surg. 2016 Apr; 151(4):347-54.
    View in: PubMed
    Score: 0.138
  10. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. Ann Surg Oncol. 2016 07; 23(7):2220-8.
    View in: PubMed
    Score: 0.136
  11. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Cancer Biol Ther. 2016; 17(2):129-38.
    View in: PubMed
    Score: 0.135
  12. AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer. 2015 Nov 14; 15:901.
    View in: PubMed
    Score: 0.134
  13. Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. Ann Surg Oncol. 2015 Nov; 22(12):3913-20.
    View in: PubMed
    Score: 0.128
  14. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. Histopathology. 2015 Apr; 66(5):627-38.
    View in: PubMed
    Score: 0.127
  15. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013 Apr; 20(4):1267-74.
    View in: PubMed
    Score: 0.109
  16. Expression of 'drugable' tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancer. Histopathology. 2011 Jul; 59(1):156-9.
    View in: PubMed
    Score: 0.099
  17. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011 Jun 15; 17(12):3943-55.
    View in: PubMed
    Score: 0.098
  18. Patterns of Care and Outcomes of Patients with Small Gastrointestinal Stromal Tumors at a High-Volume Sarcoma Center. Ann Surg Oncol. 2024 Sep 04.
    View in: PubMed
    Score: 0.062
  19. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
    View in: PubMed
    Score: 0.059
  20. Re-excision After Unplanned Excision of Soft Tissue Sarcoma is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease. Ann Surg Oncol. 2023 Jan; 30(1):480-489.
    View in: PubMed
    Score: 0.054
  21. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer. 2022 06 15; 150(12):2012-2024.
    View in: PubMed
    Score: 0.052
  22. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer. 2020 07 15; 126(14):3265-3273.
    View in: PubMed
    Score: 0.046
  23. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol. 2019 Sep; 120(3):382-388.
    View in: PubMed
    Score: 0.043
  24. Long-Term Outcomes for Patients With Desmoid Fibromatosis Treated With Radiation Therapy: A 10-Year Update and Re-evaluation of the Role of Radiation Therapy for Younger Patients. Int J Radiat Oncol Biol Phys. 2019 04 01; 103(5):1167-1174.
    View in: PubMed
    Score: 0.042
  25. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018 Sep 24; 18(1):913.
    View in: PubMed
    Score: 0.041
  26. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol. 2018 Apr; 117(5):879-885.
    View in: PubMed
    Score: 0.039
  27. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018; 7(2):e1385689.
    View in: PubMed
    Score: 0.038
  28. Clinicopathological variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. J Neurosurg. 2018 09; 129(3):805-814.
    View in: PubMed
    Score: 0.038
  29. NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response. Cancer Res. 2017 08 15; 77(16):4486-4497.
    View in: PubMed
    Score: 0.038
  30. The role of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) in peripheral nerve sheath tumours. Histopathology. 2017 May; 70(6):946-953.
    View in: PubMed
    Score: 0.037
  31. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Lab Invest. 2016 08; 96(8):885-94.
    View in: PubMed
    Score: 0.035
  32. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016 06; 29(6):582-90.
    View in: PubMed
    Score: 0.034
  33. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer. 2015 Nov 10; 15:886.
    View in: PubMed
    Score: 0.034
  34. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. J Clin Invest. 2015 Aug 03; 125(8):2965-78.
    View in: PubMed
    Score: 0.033
  35. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol. 2015 May; 143(5):672-82.
    View in: PubMed
    Score: 0.032
  36. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer. 2015 Mar 07; 14:55.
    View in: PubMed
    Score: 0.032
  37. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. Ann Surg Oncol. 2014 Aug; 21(8):2499-505.
    View in: PubMed
    Score: 0.030
  38. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer. 2013 May 15; 119(10):1868-77.
    View in: PubMed
    Score: 0.028
  39. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2012 Aug; 11(8):1758-69.
    View in: PubMed
    Score: 0.027
  40. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol. 2012 Feb; 25(2):212-21.
    View in: PubMed
    Score: 0.025
  41. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology. 2011 Sep; 59(3):556-61.
    View in: PubMed
    Score: 0.025
  42. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011 Dec 01; 117(23):5359-69.
    View in: PubMed
    Score: 0.025
  43. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011 Jan 01; 71(1):185-96.
    View in: PubMed
    Score: 0.024
  44. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer. 2011 Jan 15; 117(2):380-9.
    View in: PubMed
    Score: 0.023
  45. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res. 2010 May 01; 16(9):2591-604.
    View in: PubMed
    Score: 0.023
  46. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One. 2010 Apr 16; 5(4):e10105.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.